BNP Paribas Financial Markets Buys 6,748 Shares of Replimune Group, Inc. (NASDAQ:REPL)

BNP Paribas Financial Markets lifted its stake in shares of Replimune Group, Inc. (NASDAQ:REPL) by 81.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,011 shares of the company’s stock after purchasing an additional 6,748 shares during the quarter. BNP Paribas Financial Markets’ holdings in Replimune Group were worth $165,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of REPL. The Manufacturers Life Insurance Company boosted its holdings in Replimune Group by 24.9% in the third quarter. The Manufacturers Life Insurance Company now owns 184,208 shares of the company’s stock valued at $2,019,000 after acquiring an additional 36,689 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Replimune Group by 12.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company’s stock valued at $5,313,000 after buying an additional 52,498 shares during the last quarter. Intech Investment Management LLC bought a new position in Replimune Group in the 3rd quarter valued at $252,000. Connor Clark & Lunn Investment Management Ltd. raised its position in Replimune Group by 25.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 128,208 shares of the company’s stock worth $1,405,000 after acquiring an additional 25,939 shares during the period. Finally, LMR Partners LLP grew its holdings in Replimune Group by 145.8% during the third quarter. LMR Partners LLP now owns 82,479 shares of the company’s stock valued at $904,000 after purchasing an additional 48,920 shares during the period. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Price Performance

REPL stock opened at $11.72 on Wednesday. The firm has a 50 day simple moving average of $12.22 and a two-hundred day simple moving average of $10.58. The stock has a market cap of $801.85 million, a PE ratio of -3.84 and a beta of 1.26. Replimune Group, Inc. has a one year low of $4.92 and a one year high of $17.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.07. On average, analysts predict that Replimune Group, Inc. will post -2.91 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on REPL shares. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Jefferies Financial Group boosted their target price on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, December 4th. BMO Capital Markets raised their price target on Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a report on Friday, November 22nd. Roth Mkm started coverage on Replimune Group in a research note on Tuesday, August 27th. They set a “buy” rating and a $17.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $17.00 target price on shares of Replimune Group in a report on Friday, November 22nd. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $17.29.

Insider Activity

In other news, insider Konstantinos Xynos sold 7,246 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the sale, the insider now owns 109,885 shares of the company’s stock, valued at approximately $1,184,560.30. This represents a 6.19 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 8.80% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.